Nevertheless, the finding of EpCAM-CD81-EVs in four initial stage patients, and not in advanced stage patients or healthy donors, agrees with previous observations that advanced tumour cells lose EpCAM expression as they undergo EMT (Epithelial to Mesenchymal Transition) [65, 66]. Here, CD81 is linked to neoplasm.